Drug Profile
Research programme: galectin-3 inhibitors - G3 Pharmaceuticals
Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator G3 Pharmaceuticals; University Medical Center Groningen; University of Michigan Medical School
- Class Cardiovascular therapies; Heart failure therapies; Polysaccharides
- Mechanism of Action Galectin 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Heart failure; Renal failure
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Renal-failure in USA (PO)
- 28 Dec 2021 No recent reports of development identified for preclinical development in Heart-failure in USA (PO)
- 19 Dec 2019 Preclinical trials for Heart failure is still ongoing in USA